Miguel Martin
Complutense University and Hospital General Universitario Gregorio Maranon
Servicio De Oncologia Medica
Madrid
Spain
Name/email consistency: high
- Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Martin, M., Bell, R., Bourgeois, H., Brufsky, A., Diel, I., Eniu, A., Fallowfield, L., Fujiwara, Y., Jassem, J., Paterson, A.H., Ritchie, D., Steger, G.G., Stopeck, A., Vogel, C., Fan, M., Jiang, Q., Chung, K., Dansey, R., Braun, A. Clin. Cancer Res. (2012)
- Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. Martín, M., Makhson, A., Gligorov, J., Lichinitser, M., Lluch, A., Semiglazov, V., Scotto, N., Mitchell, L., Tjulandin, S. Oncologist (2012)
- Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Martín, M., Sánchez-Rovira, P., Muñoz, M., Baena-Cañada, J.M., Mel, J.R., Margeli, M., Ramos, M., Martínez, E., García-Saenz, J.A., Casado, A., Jaén, A.M., González-Farré, X., Escudero, M.J., Rodriguez-Martin, C., Carrasco, E. Ann. Oncol. (2011)
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Martin, M., Roche, H., Pinter, T., Crown, J., Kennedy, M.J., Provencher, L., Priou, F., Eiermann, W., Adrover, E., Lang, I., Ramos, M., Latreille, J., Jagiełło-Gruszfeld, A., Pienkowski, T., Alba, E., Snyder, R., Almel, S., Rolski, J., Munoz, M., Moroose, R., Hurvitz, S., Baños, A., Adewoye, H., Hei, Y.J., Lindsay, M.A., Rupin, M., Cabaribere, D., Lemmerick, Y., Mackey, J.R. Lancet Oncol. (2011)
- Adjuvant docetaxel for high-risk, node-negative breast cancer. Martín, M., Seguí, M.A., Antón, A., Ruiz, A., Ramos, M., Adrover, E., Aranda, I., Rodríguez-Lescure, A., Grosse, R., Calvo, L., Barnadas, A., Isla, D., Martinez del Prado, P., Ruiz Borrego, M., Zaluski, J., Arcusa, A., Muñoz, M., López Vega, J.M., Mel, J.R., Munarriz, B., Llorca, C., Jara, C., Alba, E., Florián, J., Li, J., López García-Asenjo, J.A., Sáez, A., Rios, M.J., Almenar, S., Peiró, G., Lluch, A. N. Engl. J. Med. (2010)
- Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Martín, M., Rodríguez-Lescure, A., Ruiz, A., Alba, E., Calvo, L., Ruiz-Borrego, M., Santaballa, A., Rodríguez, C.A., Crespo, C., Abad, M., Domínguez, S., Florián, J., Llorca, C., Méndez, M., Godes, M., Cubedo, R., Murias, A., Batista, N., García, M.J., Caballero, R., de Alava, E. Breast Cancer Res. Treat. (2010)
- A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. Martin, M., Blasinska-Morawiec, M., Salas, J.F., Falcon, S., Rolski, J., Ferrari, B.L., Gulyas, S., Liu, Y., Benhadji, K.A. Clin. Breast Cancer (2009)
- Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Martín, M., García-Sáenz, J.A., Maestro De las Casas, M.L., Vidaurreta, M., Puente, J., Veganzones, S., Rodríguez-Lajusticia, L., De la Orden, V., Oliva, B., De la Torre, J.C., López-Tarruella, S., Casado, A., Sastre, J., Díaz-Rubio, E. Anticancer Res. (2009)
- Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Martín, M., Esteva, F.J., Alba, E., Khandheria, B., Pérez-Isla, L., García-Sáenz, J.A., Márquez, A., Sengupta, P., Zamorano, J. Oncologist (2009)
- Unravelling the mystery of the TACT trial. Martin, M. Lancet (2009)
- Prognostic and predictive factors and genetic analysis of early breast cancer. Martín, M., González Palacios, F., Cortés, J., de la Haba, J., Schneider, J. Clin. Transl. Oncol (2009)
- Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín, M., Rodríguez-Lescure, A., Ruiz, A., Alba, E., Calvo, L., Ruiz-Borrego, M., Munárriz, B., Rodríguez, C.A., Crespo, C., de Alava, E., López García-Asenjo, J.A., Guitián, M.D., Almenar, S., González-Palacios, J.F., Vera, F., Palacios, J., Ramos, M., Gracia Marco, J.M., Lluch, A., Alvarez, I., Seguí, M.A., Mayordomo, J.I., Antón, A., Baena, J.M., Plazaola, A., Modolell, A., Pelegrí, A., Mel, J.R., Aranda, E., Adrover, E., Alvarez, J.V., García Puche, J.L., Sánchez-Rovira, P., Gonzalez, S., López-Vega, J.M. J. Natl. Cancer Inst. (2008)
- Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Martin, M., Mackey, J., Vogel, C. Breast (2007)
- Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Martín, M., Ruiz, A., Muñoz, M., Balil, A., García-Mata, J., Calvo, L., Carrasco, E., Mahillo, E., Casado, A., García-Saenz, J.A., Escudero, M.J., Guillem, V., Jara, C., Ribelles, N., Salas, F., Soto, C., Morales-Vasquez, F., Rodríguez, C.A., Adrover, E., Mel, J.R. Lancet Oncol. (2007)
- Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Martin, M. Womens. Health. (Lond. Engl) (2006)
- The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Martín, M., Mahillo, E., Llombart-Cussac, A., Lluch, A., Munarriz, B., Pastor, M., Alba, E., Ruiz, A., Antón, A., Bermejo, B. Clin. Transl. Oncol (2006)
- Clinical experience with pemetrexed in breast cancer. Martin, M. Semin. Oncol. (2006)
- Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Martín, M., Lluch, A., Seguí, M.A., Ruiz, A., Ramos, M., Adrover, E., Rodríguez-Lescure, A., Grosse, R., Calvo, L., Fernandez-Chacón, C., Roset, M., Antón, A., Isla, D., del Prado, P.M., Iglesias, L., Zaluski, J., Arcusa, A., López-Vega, J.M., Muñoz, M., Mel, J.R. Ann. Oncol. (2006)
- Adjuvant docetaxel for node-positive breast cancer. Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, A., Fornander, T., Hainsworth, J., Coleman, R., Vinholes, J., Modiano, M., Pinter, T., Tang, S.C., Colwell, B., Prady, C., Provencher, L., Walde, D., Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, S., Jacobs, P., Murawsky, M., Riva, A., Vogel, C. N. Engl. J. Med. (2005)
- Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Martin, M., García-Donas, J., Casado, A., de la Gándara, I., Pérez-Segura, P., García-Saenz, J.A., Ibáñez, G., Loboff, B., García-Ledo, G., Moreno, F., Grande, E., Diaz-Rubio, E. Clin. Breast Cancer (2004)
- Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Martin, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massuti, B., Lizon, J., Camps, C., Carrato, A., Casado, A., Candel, M.T., Albanell, J., Aranda, J., Munarriz, B., Campbell, J., Diaz-Rubio, E. Ann. Oncol. (2003)
- Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Martin, M., Spielmann, M., Namer, M., duBois, A., Unger, C., Dodwell, D., Vodvarka, P., Lind, M., Calvert, H., Casado, A., Zelek, L., Lluch, A., Carrasco, E., Kayitalire, L., Zielinski, C. Ann. Oncol. (2003)